Prostate cancer is the second leading cause of cancer-related mortality, and accounts for 10% of cancer-related deaths in American men.1 It is estimated that 1 in 9 men will have prostate cancer during their lifetime, and an estimated 161,363 new cases and 26,730 prostate cancer–related deaths are expected in the United States in 2017.2 Although genetic aberrations are often present in malignant prostate epithelial cells, the growth of these cells depends on androgen receptor activation and signaling, much like normal prostate cells. Consequently, androgen-deprivation therapy (ADT) remains a vital therapeutic approach in the treatment of advanced prostate cancer. ADT involves the use of bilateral orchiectomy (ie, surgical castration) or the administration of a gonadotropin-releasing hormone agonist, such as leuprolide, goserelin, or triptorelin (ie, medical castration). Anti-androgens, such as the androgen receptor antagonists nilutamide, flutamide, or bicalutamide, can be combined with medical or surgical castration to provide combined androgen blockade.
ADT is initially effective as observed by a reduction in the tumor volume and the expression of the androgen-dependent gene, prostate-specific antigen (PSA). However, this is unvaryingly followed by the recurrence of a more aggressive and often fatal phenotype within a median period of 2 to 3 years.3 This recurrent prostate cancer is referred to as castrate-resistant prostate cancer (CRPC) because despite anorchid levels of systemic testosterone, proliferation of CRPC cells continue to depend on androgen receptor activation. Androgen receptor reactivation within these cells represents an adaptive stress response after exposure to ADT and involves dysregulation of the androgen receptor axis.
Several mechanisms that result in restoration of androgen receptor activity within the tumor and increased expression of prosurvival factors have been identified in CRPC. These mechanisms involve elevated intratumoral biosynthesis and/or changes to the androgen receptor and androgen receptor signaling that reduce the need for the potent androgens, testosterone and 5α-dihydrotestosterone (DHT).3-6
Testosterone is primarily produced in the Leydig cells of the testes, which account for approximately 90% of the testosterone production in the body, with the adrenal gland contributing the remainder. Testosterone can be converted into the more potent androgen, DHT, in the tissues by 5α-reductases. ADT targets testicular production of androgens and produces a dramatic reduction in systemic levels of testosterone (<50 ng/dL). Despite the castrate level of systemic testosterone and DHT, intratumoral levels of these androgens in CRPC are increased relative to non-CRPC tumors, and are sufficient to activate the androgen receptor and drive tumor proliferation. The testosterone and DHT levels within the tumors are maintained by an upregulation of enzymes that catalyze important steps in androgen biosynthesis (Figure 1). These enzymes include cytochrome (CY)P45017A1, aldo-keto reductase 1C3 (AKR1C3), and 3β-hydroxysteroid dehydrogenase (3β-HSD).5,7
These enzymes catalyze the conversion of adrenal precursors—dehydroepiandrosterone (DHEA) and 4-androstene-3,17-dione (Δ4-Adione)—to testosterone and DHT, as well as the denovo biosynthesis of androgens from cholesterol (Figure 1). Recently, Chang and colleagues reported a gain of function mutation in type 1 3β-HSD (3β-HSD1) in CRPC cells.8 This point mutation increases the stability and half-life of the protein, which leads to increased DHT biosynthesis.
The importance of renewed androgen biosynthesis in CRPC and the potential therapeutic utility of inhibitors of androgen biosynthesis are underscored by the remarkable clinical efficacy and subsequent US Food and Drug Administration (FDA) approval of abiraterone acetate, a CYP17A1 inhibitor, for the treatment of patients with CRPC. CYP17A1 catalyzes the 2 consecutive reactions that convert pregnenolone to DHEA and progesterone to Δ4-Adione. Δ4-Adione is subsequently reduced to testosterone by AKR1C3. This has spurred intensive efforts into the discovery and development of other compounds that target CYP17A1, AKR1C3, and other androgen biosynthetic enzymes.9-11
The androgen receptor is a ligand (androgen)-activated transcription factor that belongs to the nuclear receptor superfamily. In the absence of agonist occupancy, the androgen receptor is resident in the cytoplasm bound to chaperone proteins, such as heat shock proteins. Binding of an agonist induces a conformational change in the receptor that causes it to dissociate from the inactive complex. The bound receptor homodimerizes and translocates into the nucleus, where it binds specific DNA sequences known as androgen response elements, and facilitates the transcription of androgen-responsive genes that bring about the plethora of physiologic effects associated with androgens.
Adaptive genetic changes in the androgen receptor represent another route through which the tumor escapes the growth-suppressive effect of ADT. These changes alter androgen receptor transcriptional activity by affecting the androgen receptor and/or its binding partners within the cell, and include androgen receptor upregulation, androgen receptor mutation, development of constitutively active androgen receptor splice variants (AR-Vs), and alteration in androgen receptor co-factors.3,12
The androgen receptor has 3 functional domains corresponding to the N-terminal domain, the DNA-binding domain, and the carboxy-terminal ligand-binding domain (LBD).13 Androgen receptor upregulation has been consistently observed in CRPC samples after ADT. Androgen receptor upregulation causes an increase in androgen receptor mRNA and protein, which results in androgen receptor ligand hypersensitivity.13-15 The androgen receptor ligand hypersensitivity reduces the androgen threshold required for significant androgen receptor activation, which allows for androgen receptor signaling in the presence of the significantly reduced levels of androgens brought about by ADT. Chen and colleagues showed that a 3- to 5-fold increase in androgen receptor mRNA was sufficient for the tumor to bypass the growth-inhibitory effects of ADT.16
Most of the androgen receptor mutations seen in prostate cancer after ADT occur in the androgen receptor LBD and lead to relaxation of the androgen receptor ligand specificity. These mutated androgen receptors are usually characterized by an increased responsiveness to weak androgens, such as DHEA, Δ4-Adione, or 5α-Adione, as well as to nonandrogen steroid hormones, such as estrogens, progesterone, or cortisol.17-22 Antagonist to agonist conversion was also observed with some of these mutated androgen receptors. A notable example is the androgen receptor T877A mutation (ART877A), which involves the replacement of a threonine residue with an alanine residue at position 877. The ART877A is activated by estrogen, progesterone, and anti-androgens, such as bicalutamide or flutamide.23-26 The activation of mutated androgen receptors by anti-androgens is consistent with the reduction in prostate tumor markers and clinical improvement in some patients after cessation of anti-androgen therapy, a phenomenon that is often referred to as anti-androgen withdrawal syndrome.27,28
The expression of AR-Vs, isoforms that lack or have a truncated LBD, is now well-recognized as a tumor adaptive response to ADT. The absence of the LBD obviates the need for agonist binding to trigger androgen receptor signaling, which makes these AR-Vs constitutively active.29-31 It also renders traditional androgen receptor antagonists ineffective for the same reason. Several of these variants have been identified, with AR-V7 being the most common variant seen in CRPC.32,33
The continued requirement of a functional androgen receptor axis in CRPC development and progression indicates that new-generation anti-androgens that exploit ≥1 steps of the androgen receptor signaling cascade can be effective in treating CRPC. This observation provided a backdrop for the development of enzalutamide.34
Development of Enzalutamide
Enzalutamide was discovered in a screen that evaluated the androgen receptor antagonism of compounds in a setting of elevated androgen receptor expression designed to mimic CRPC.34 Enzalutamide is a 3-ringed thiohydantoin derivative; the rings are labeled A, B, and C, as shown in Figure 2.
Enzalutamide was derived after modification of a nonsteroidal androgen receptor agonist, RU59063, which showed excellent androgen receptor affinity and was more potent than DHT (Figure 2).34-36 The binding of the nonsteroidal agonist with higher potency triggered the search for a nonsteroidal androgen receptor antagonist. The aim was to modify RU59063 to produce an androgen receptor antagonist. Activities of these RU59063 analog were compared with the androgen receptor antagonist bicalutamide. Different analog of RU59063 were prepared with different substituents at N1 to provide adequate binding at the androgen receptor. This led to the development of N1-phenyl ring–substituted analog.
The N1-phenyl group can be substituted with various electron-donating and -withdrawing substituents, such as alkyl, phenyl, cyano, and nitro, and all of them are effective as androgen receptor antagonists. However, the presence of an electron donating at the para (p-) position of the N1-phenyl ring decreases the half-life of the compound and increases its elimination. Hence, the electron withdrawing, such as amide, is preferred at this position (Figure 2).
The presence of dimethyl groups at C5 of the thiohydantoin ring also resulted in better antagonist activity. Other modifications—such as the thiocarbonyl at C2 in enzalutamide compared with a carbonyl group at the same position in RU59063—created a more potent antagonist. These modifications of RU59063 led to the development of enzalutamide. Compared with bicalutamide, enzalutamide displayed excellent androgen receptor antagonist activity (IC50: 122 nM) and a desirable pharmacokinetic and toxicologic profile.
Absorption and Distribution
The pharmacokinetics of enzalutamide were studied in patients and in healthy volunteers. Enzalutamide is well-absorbed after oral administration, with approximately 85% of the administered dose being absorbed.37 The extent of absorption of enzalutamide after oral administration is not affected by the presence of food.37,38 Enzalutamide undergoes extensive extravascular distribution with a volume of distribution of 110 L. When patients with metastatic CRPC took the 160-mg oral dose of enzalutamide, the median time to reach the maximum plasma concentration (Cmax) was 1 hour, with a range from 30 minutes to 3 hours.37,38 Steady-state levels are achieved when enzalutamide is taken daily for 28 days and the accumulation of enzalutamide is approximately 8.3-fold greater than a single dose.37,38 Once the steady-state level is reached, the mean Cmax level is 16.6 µg/mL for enzalutamide and 12.7 µg/mL for N-desmethyl enzalutamide, the active metabolite of enzalutamide. Enzalutamide and N-desmethyl enzalutamide are 97% to 98% and 95%, respectively, plasma protein bound. The mean peak-to-trough ratio is 1.25, demonstrating a low fluctuation in daily plasma concentrations of enzalutamide.38
Metabolism and Elimination
The primary route of elimination of enzalutamide is hepatic, with the 2 main enzymes involved being CYP2C8 and CYP3A4. CYP2C8 converts enzalutamide to N-desmethyl enzalutamide, an active metabolite for the drug. There is conversion to an inactive carboxylic acid metabolite as well. In patients with metastatic CRPC, the mean apparent clearance was 0.56 L hourly, and the mean terminal half-life was 5.8 days. The half-life for N-desmethyl enzalutamide is approximately 7.8 to 8.6 days.38
The patient’s age or body weight does not have a clinically significant impact on the pharmacokinetics of enzalutamide. Likewise, the clearance of enzalutamide is not changed in patients with mild or moderate renal or hepatic impairment. However, not enough data are available to determine how severe renal or hepatic impairment or end-stage renal disease affects the clearance of the drug. Enzalutamide is pregnancy category X, and women who are or may become pregnant should not ingest or handle the drug.37,38
Mechanism of Action
Enzalutamide is a second-generation anti-androgen. The second-generation anti-androgens were developed because the first-generation anti-androgens acted as partial agonists in advanced-stage prostate cancer caused by the overexpression of the androgen receptor and the mutations in androgen receptor LBD. Enzalutamide has a high binding affinity for the carboxy-terminal LBD of the androgen receptor, and is active in the presence of androgen receptor overexpression and mutations that render other androgen receptor antagonists ineffective.13,37 Enzalutamide competes with testosterone and DHT binding to the androgen receptor LBD, and consequently inhibits androgen receptor signaling. Unlike bicalutamide, enzalutamide also inhibits nuclear translocation and transcription.37
Data from clinical trials indicate that enzalutamide is a strong CYP3A4 inducer and a moderate inducer of CYP2C9 and CYP2C19.36,37 Time-dependent inhibition of CYP1A2 has been observed with enzalutamide treatment.36 Enzalutamide and N-desmethyl enzalutamide are 2 inhibitors of P-glycoprotein.36,37 Therefore, caution should be used when co-administering enzalutamide with substrates of P-glycoprotein, CYP2C9, CYP2C19, and CYP3A4. The pharmacokinetics of drugs that are substrates of P-glycoprotein (eg, loperamide, vinblastine) may be affected when administered with enzalutamide. Use of drugs that have a narrow therapeutic index and are substrates of CYP2C9, CYP2C19, and CYP3A4 enzymes should be avoided with enzalutamide (Table 1).37
Enzalutamide was approved by the FDA for the treatment of men with metastatic CRPC based on the results of the AFFIRM clinical trial.39 In this randomized, phase 3, placebo-controlled study, 1199 men with CRPC were randomized to enzalutamide 160 mg (four 40-mg capsules) once daily or to placebo in a 2:1 ratio. All participants had received ≥1 docetaxel-containing chemotherapy regimens before enrollment in the study. The study design was almost identical to that of the COU-AA-301 trial, which led to the FDA approval of abiraterone acetate, except for the use of prednisone or other glucocorticoids with the latter.40
Abiraterone acetate is a potent inhibitor of androgen synthesis in the adrenal gland, testes, and prostate tumor. It requires concomitant steroid use to prevent the hypokalemia, fluid retention, and hypertension from mineralocorticoid excess caused by adrenal blockade.40 In contrast, enzalutamide does not lower androgen levels; rather, it inhibits androgen receptor signaling by competitively inhibiting the binding of androgens, without stimulating the receptor. Tumor growth requires androgen binding to the receptor, followed by nuclear translocation. Thus, inhibition of androgen receptor signaling is important in preventing disease progression.
The primary end point in AFFIRM was overall survival (OS), which was 18.4 months in the treatment group and 13.6 months in the placebo group.39 This correlated to a significant 37% mortality risk reduction with enzalutamide versus placebo. This benefit was seen across all subgroups, even after adjustment for baseline prognostic factors. Secondary end points, including quality of life, were also significantly improved. After the interim analysis, the study was unblinded, and the placebo group was offered enzalutamide.
Although adverse events were more common in the enzalutamide group, they were generally mild and included fatigue, diarrhea, hot flashes, musculoskeletal pain, and headache. These effects could be caused by the further inhibition of androgen receptor signaling in normal tissues. Interestingly, the AFFIRM study also demonstrated reduced incidence of grades 3 and 4 adverse events with enzalutamide compared with placebo. In addition, the median time to first grade 3 or 4 adverse event was lengthened by 8.4 months in the enzalutamide group. The most common of such events were fatigue and diarrhea. This finding suggests that the toxicity associated with placebo was mainly caused by the underlying disease.
No differences in cardiac disorders or in development of metabolic syndrome were reported. Convulsions have been reported as a dose-dependent toxic effect in animal studies, and seizures were seen at doses >360 mg in the phase 1 and 2 clinical trials of enzalutamide.41,42 Of the 5 patients in the treatment group of the AFFIRM trial who reported seizures, 4 had identifiable seizure causes, predisposing them to a heightened seizure risk.39 Regardless, the prevailing recommendation is to use enzalutamide with caution in patients with a history of seizure disorders or other predisposing factors.
The results of the AFFIRM trial, as well as the reported survival benefit of abiraterone plus prednisone, underscore the notion that androgen receptor signaling contributes to disease progression, even in the presence of castrate levels of testosterone.39,40 However, although enzalutamide reduced the rate of disease progression compared with placebo, there was still a large proportion (42%) of patients who required additional antineoplastic therapy after cessation of the study drug.39 In addition, PSA levels were increased in the majority of patients whose disease progressed after enzalutamide treatment. This suggests that tumor growth in these patients continues to be driven by the androgen receptor, and they may benefit from further hormonal interventions. It was also reasoned that if the androgen receptor is still driving the development and progression of CRPC, enzalutamide would be active in these patients regardless of previous exposure to docetaxel.43
This reasoning proved to be correct, based on the results of another phase 3 clinical trial, the PREVAIL study, which led to the FDA approval of enzalutamide for the treatment of metastatic CRPC in chemotherapy-naïve patients. The PREVAIL study included 1717 chemotherapy-naïve patients with metastatic CRPC and compared enzalutamide with placebo.43 Patients were required to continue ADT but had not received chemotherapy or abiraterone acetate before the study. The patients were randomly assigned to receive enzalutamide 160 mg or placebo once daily, with or without food. Primary end points were OS and progression-free survival (PFS).43
At 1 year, PFS was significantly better with enzalutamide, at 65% compared with 14% with placebo, resulting in an 81% risk reduction for disease progression or death (95% confidence interval [CI], 0.15-0.23; P <.001).43 At a median 22-month follow-up, significantly fewer deaths were reported in the active treatment group compared with the placebo group (28% vs 35%, respectively), resulting in a 29% reduction in mortality risk (95% CI, 0.60-0.84; P <.001). This correlated to a median OS of 32.4 months for enzalutamide compared with 30.2 months for placebo. This improvement was seen across all subgroups.43
As was done in the AFFIRM trial, the PREVAIL study was halted early and was unblinded at this point, and the placebo group was offered the study drug. In addition, subsequent antineoplastic therapy, most often docetaxel or abiraterone acetate, was given to 40% of patients in the enzalutamide group versus 70% in the placebo group, and enzalutamide delayed the time to chemotherapy initiation by 17 months.43 The delay of initiating active treatment in the placebo group may account for some of the benefits of enzalutamide. This point is supported by the finding that abiraterone acetate also was associated with a more pronounced delay of disease progression when it was used before than after chemotherapy.40,44 However, no studies to date have directly looked at the effect of the timing of therapy in patients with metastatic CRPC.
The PREVAIL trial demonstrated that the safety profile of enzalutamide was consistent with previous data. Enzalutamide was again shown to prolong the time to first grade 3 or 4 adverse event by 9 months.43 However, unlike the AFFIRM study, grade 3 or 4 adverse events were more common in the enzalutamide group than in the placebo group (43% vs 37%, respectively).43 Even after adjustment for a longer exposure for the treatment group, the rate of adverse events was higher with enzalutamide than with placebo, most notably hypertension, although this was not attributed to mineralocorticoid excess. Notably absent was a risk for seizures in the PREVAIL trial, with 1 patient in each study group having a seizure. Both of these patients had an unreported history of seizures at the time of enrollment.43
In the COU-AA-302 clinical trial, abiraterone acetate plus prednisone was found to benefit chemotherapy-naïve patients with CRPC, which led to its FDA approval in this setting.44 Although the results reported at 27.2 months showed a trend toward improved OS for the treatment group compared with prednisone alone, the study failed to reach significance at the time. However, in the final OS analysis at 4 years, the clinical and statistical survival advantage of abiraterone acetate was confirmed.45 It is worth noting, however, that COU-AA-302 had excluded patients with visceral metastases, whereas the AFFIRM and the PREVAIL studies did not. Visceral metastases confer a poorer prognosis than nonvisceral sites; therefore, exclusion of such patients may inflate the results for abiraterone acetate compared with enzalutamide.46
In late 2014, the American Society of Clinical Oncology and the National Comprehensive Cancer Network (NCCN) updated their respective prostate cancer guidelines to reflect the new data regarding enzalutamide.47,48 Both guidelines now recommend abiraterone acetate plus prednisone or enzalutamide as first-line therapy in patients with metastatic CRPC, regardless of previous chemotherapy status. In addition, enzalutamide carries the benefit of a first-line recommendation for those with visceral metastases.47,48
Despite establishing enzalutamide among the various standards of care for patients with metastatic CRPC, the AFFIRM and PREVAIL studies demonstrated only approximately an 8- to 11-month time frame before disease progression with enzalutamide.39,43 A similar time to progression was noted with abiraterone acetate in its respective studies.40,44 This has raised concerns regarding resistance to enzalutamide. Indeed, the issue of resistance, even to newer androgen and androgen receptor–targeted therapies, remains a continuing challenge in the treatment of patients with CRPC. Such concerns have led to the suggestion that resistance to enzalutamide can be overcome by subsequent therapy with abiraterone acetate and vice versa, given the nonoverlapping mechanisms of action of the 2 drugs. Similarly, it is generally believed that combination therapy should reduce the incidence of resistance to either drug.
Enzalutamide and abiraterone acetate have been included in the NCCN recommendations for subsequent therapy after disease progression with each drug.48 However, this is based on several small studies examining the sequencing of abiraterone acetate and enzalutamide. When abiraterone acetate was given after disease progression with enzalutamide, few patients achieved a ≥50% PSA reduction, and the time to progression was only approximately 3 to 4 months.49,50 Likewise, when enzalutamide was given after disease progression with abiraterone acetate, the PSA response rate was low, and the median time to progression with enzalutamide was 2.8 to 4 months.51,52 The blunted response to enzalutamide in patients with resistance to abiraterone acetate was without regard to previous exposure to docetaxel. These data, although limited, would suggest significant cross-resistance between the 2 agents as a result of similar or overlapping mechanisms of acquired tumor resistance.
Theoretically, combination therapy may be effective in overcoming or delaying resistance mechanisms in the same fashion that highly active antiretroviral therapy is effective in HIV/AIDS treatment. Clinical trials are currently underway to examine this theory, and interim results are promising. In one such study, PSA decline of ≥50% was reported in approximately 76% of patients, and disease progression in approximately 12%. In addition, a favorable side-effect profile has been reported thus far.53
Several resistance mechanisms have been elucidated in enzalutamide-resistant prostate tumors. It is well-established that androgens and androgen receptor activation continue to drive tumor growth in patients with CRPC, which explains the efficacy of anti-androgen therapy, such as abiraterone acetate or enzalutamide. Indeed, it is these mechanisms of resistance that abiraterone acetate and enzalutamide target. As observed in the phase 3 studies discussed earlier, of the patients with CRPC who initially respond to hormonal therapy, nearly all will acquire secondary resistance.40,43,44,51
Much like the resistance to ADT, bicalutamide, and other first-generation androgen receptor antagonists, an increase in androgen biosynthesis enzymes, presence of androgen receptor mutations, and constitutively active androgen receptor splice variants lacking the C-terminal–binding domain have been observed after treatment with enzalutamide.54-57 The presence of a spontaneous F876L mutation on the androgen receptor (ARF876L) was observed in preclinical models of prostate cancer cells and xenografts that developed resistance to enzalutamide.55,56
Genetically engineered prostate cancer cells expressing this androgen receptor mutation were also resistant to enzalutamide. ARF876L occurs in the hypermutable androgen receptor LBD and confers androgen receptor agonist properties on enzalutamide, which allows for sustained growth of the treated cells. This indicates the possibility of an enzalutamide withdrawal syndrome, although few cases have been reported.58,59 Notably, this mutation, although resistant to enzalutamide, increases tumor cells’ sensitivity to bicalutamide, which underscores the need for an evaluation of the specific mutation present in an individual patient to determine the best course of therapy.
Another mechanism that has been implicated in enzalutamide resistance in preclinical models is an increased expression of AKR1C3.57 Patients receiving enzalutamide have been reported to have elevated testosterone levels in the bone marrow, and enzalutamide-resistant prostate cancer cells were found to produce several-fold increased levels of testosterone and DHT.57,60,61 This is consistent with the prostate cancer cells’ adaptive response to the inhibition of androgen receptor activation. AKR1C3 is an important enzyme in androgen biosynthesis that is highly upregulated in CRPC.5,7,62,63 It catalyzes the conversion of weak androgens—Δ4-Adione and 5α-Adione—to testosterone and DHT, respectively.64,65 Liu and colleagues showed that an increase in AKR1C3 expression and activity was a critical mechanism that drives enzalutamide resistance in prostate cancer cells and xenografts.57 Enzalutamide sensitivity was restored after AKR1C3 knockdown or inhibition by small molecules. This suggests that AKR1C3 inhibitors could potentially be used independently for the treatment of metastatic CRPC, or in addition to enzalutamide, to reverse or limit the resistance to enzalutamide.9,10,66
Increased expression of AR-Vs, particularly AR-V7, has also been associated with enzalutamide resistance. The clinical relevance of AR-V7 on the efficacy of abiraterone acetate and enzalutamide was tested in a small, prospective study of men with metastatic CRPC who were beginning therapy with enzalutamide or with abiraterone acetate.67 Antonarakis and colleagues measured a baseline AR-V7 status in circulating tumor cells to predict response or resistance to anti-androgen therapy. The 62 patients with detectable circulating tumor cells were equally randomized to receive enzalutamide or abiraterone acetate. Twelve of the 31 patients in the enzalutamide group and 6 of the 31 patients in the abiraterone group had detectable AR-V7 mRNA (Table 2).67
A total of 50% of patients with previous enzalutamide exposure had detectable AR-V7 compared with 15% who had no previous exposure. Similarly, 55% of the patients who had previous exposure to abiraterone acetate had detectable AR-V7 compared with 9% who never received the drug. In addition, 6 patients (4 in the enzalutamide group and 2 in the abiraterone acetate group) had converted from negative AR-V7 status to positive AR-V7 status during the course of treatment.67 This supports the involvement of AR-V7 as a mechanism of resistance to the drugs. Although 53% of the AR-V7–negative patients achieved a PSA response, defined as ≥50% PSA reduction, during treatment with enzalutamide, none of the AR-V7–positive patients achieved the same threshold after treatment with enzalutamide.67
Similarly, none of the AR-V7–positive patients had a PSA response to abiraterone acetate. In addition, of the patients who became AR-V7–positive after treatment initiation, only 17% achieved a PSA response; this is in contrast to the 68% of patients who remained AR-V7–negative throughout treatment and had a PSA response. These observations translated to a significant reduction in OS in AR-V7–positive patients.67
These results demonstrate a strong association between AR-V7 status and resistance to enzalutamide and abiraterone acetate. However, as indicated by the authors, it is possible that AR-V7 is simply a marker of higher disease burden.67 These findings need to be replicated in a larger cohort of patients to establish the role of AR-V7 in enzalutamide resistance, and potentially use it as a biomarker to facilitate individualized treatment of CRPC.
Should AR-V7 be validated as a mechanism of resistance, drugs that target the N-terminal domain would theoretically inhibit the full-length androgen receptor, as well as the AR-Vs. Indeed, inhibitors of androgen receptor N-terminal domain, such as EPI-001, are in the early stages of development and may represent another step forward in the treatment of CRPC.68,69 EPI-001 binds covalently to the androgen receptor N-terminal domain and irreversibly inhibits androgen receptor transcriptional activity.68,70 Because it does not bind to the androgen receptor LBD, EPI-001 cannot be outcompeted by androgens, and is able to inhibit full-length androgen receptors and AR-Vs, which are correlated with resistance to enzalutamide and abiraterone acetate.
Enzalutamide is a rationally designed, second-generation anti-androgen that has been approved by the FDA for the treatment of patients with metastatic CRPC without regard to previous docetaxel therapy. Despite the initial efficacy, resistance to enzalutamide eventually occurs. This may be the result of selective pressure on the tumor after enzalutamide therapy. Although the mechanisms of resistance to enzalutamide have not been completely elucidated, these adaptive changes involve reactivation of the androgen axis. The continued dependence on androgen receptors and androgens by prostate cancers that have progressed with enzalutamide provides opportunities for newer agents that target the androgen axis to be used concurrently with enzalutamide, or after resistance develops. However, these drugs are likely to be effective for a limited time, as the tumor will invariably progress. The findings of the combined use of abiraterone acetate and enzalutamide will be critical to optimizing the use of these agents. The outcome of this study will also have implications for the development and use of new agents targeting the androgen receptor axis.
Author Disclosure Statement
Dr Adeniji, Dr Kaland, Dr Lynch, and Dr Mody have no conflicts of interest to report.
1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. National Cancer Institute SEER Program. Cancer stat facts: prostate cancer. http://seer.cancer.gov/statfacts/html/prost.html. Accessed December 21, 2015.
3. Knudsen KE, Penning TM. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab. 2010;21: 315-324.
4. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res. 2009;15:4792-4798.
5. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006;66:2815-2825.
6. Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008;68:6407-6415.
7. Pfeiffer MJ, Smit FP, Sedelaar JP, Schalken JA. Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol Med. 2011;17:657-664.
8. Chang KH, Li R, Kuri B, et al. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell. 2013;154:1074-1084.
9. Liedtke AJ, Adeniji AO, Chen M, et al. Development of potent and selective indomethacin analogs for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer. J Med Chem. 2013;45:2429-2446.
10. Adeniji AO, Twenter BM, Byrns MC, et al. Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships. J Med Chem. 2012;55:2311-2323.
11. Yin L, Hu Q. CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents. Nat Rev Urol. 2014;11:32-42.
12. Wyatt AW, Gleave ME. Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol Med. 2015;7:878-894.
13. Wong YN, Ferraldeschi R, Attard G, de Bono J. Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nat Rev Clin Oncol. 2014;11:365-376.
14. Ford OH III, Gregory CW, Kim D, et al. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J Urol. 2003;170:1817-1821.
15. Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer. 2003;89:552-556.
16. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33-39.
17. Byrns MC, Mindnich R, Duan L, Penning TM. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride. J Steroid Biochem Mol Biol. 2012;130:7-
18. Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995;332:1393-1398.
19. Culig Z, Hobisch A, Cronauer MV, et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol. 1993;7:1541-1550.
20. Zhao XY, Malloy PJ, Krishnan AV, et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med. 2000;6:703-706. Erratum in: Nat Med. 2000;6:939.
21. Tan J, Sharief Y, Hamil KG, et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol. 1997;11:450-459.
22. Veldscholte J, Voorhorst-Ogink MM, Bolt-de Vries J, et al. Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids. Biochim Biophys Acta. 1990;1052:187-194.
23. Hara T, Miyazaki J, Araki H, et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. 2003;63:149-153.
24. Schuurmans AL, Bolt J, Veldscholte J, Mulder E. Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion. J Steroid Biochem Mol Biol. 1990;37:849-853.
25. Veldscholte J, Ris-Stalpers C, Kuiper GG, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun. 1990;173:534-540.
26. Wilding G, Chen M, Gelmann EP. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate. 1989;14:103-115.
27. Paul R, Breul J. Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance. Drug Saf. 2000;23:381-390.
28. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004;22:1025-1033.
29. Dehm SM, Schmidt LJ, Heemers HV, et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008;68:5469-5477.
30. Hu R, Dunn TA, Wei S, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009;69:16-22.
31. Sun S, Sprenger CC, Vessella RL, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 2010;120:2715-2730.
32. Lu C, Luo J. Decoding the androgen receptor splice variants. Transl Androl Urol. 2013;2:178-186.
33. Zhang X, Morrissey C, Sun S, et al. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One. 2011;6:e27970.
34. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787-790.
35. Schuurmans AL, Bolt J, Voorhorst MM, et al. Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids. Int J Cancer. 1988;42:917-922.
36. Jung ME, Ouk S, Yoo D, et al. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem. 2010;53:2779-2796.
37. Sanford M. Enzalutamide: a review of its use in metastatic, castration-resistant prostate cancer. Drugs. 2013;73:1723-1732.
38. Xtandi (enzalutamide) capsules [prescribing information]. San Francisco, CA: Astellas Pharma; October 2015.
39. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187-1197.
40. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995-2005.
41. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010;375:1437-1446.
42. Foster WR, Car BD, Shi H, et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate. 2011;71:480-488.
43. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424-433.
44. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138-148.
45. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152-160.
46. Halabi S, Kelly WK, Zhou H, et al. The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): a meta-analysis of five phase III trials. J Clin Oncol. 2014;32(15 suppl):Abstract 5002.
47. Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline. J Clin Oncol. 2014;32:3436-3448.
48. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Prostate Cancer. Version 1.2015. October 24, 2014. www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed May 1, 2016.
49. Loriot Y, Bianchini D, Ileana E, et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol. 2013;24:1807-1812.
50. Noonan KL, North S, Bitting RL, et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013;24:1802-1807.
51. Schrader AJ, Boegemann M, Ohlmann CH, et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Euro Urol. 2014;65:30-36.
52. Cheng H, Gulati R, Azad A, et al. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer Prostatic Dis. 2015;18:122-127.
53. Efstathiou E, Titus MA, Wen S, et al. Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol. 2014;32(15 suppl):Abstract 5000.
54. Li Y, Chan SC, Brand LJ, et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013;73:483-489.
55. Korpal M, Korn JM, Gao X, et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov. 2013;3:1030-1043.
56. Joseph J, Lu N, Qian J, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 2013;3:1020-1029.
57. Liu C, Lou W, Zhu Y, et al. Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer. Cancer Res. 2015;75:1413-1422.
58. Phillips R. Prostate cancer: an enzalutamide antiandrogen withdrawal syndrome. Nat Rev Urol. 2014;11:366.
59. Rodriguez-Vida A, Bianchini D, Van Hemelrijck M, et al. Is there an antiandrogen withdrawal syndrome with enzalutamide? BJU Int. 2015;115:373-380.
60. Efstathiou E, Titus MA, Tsavachidou D, et al. MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: a preliminary report. J Clin Oncol. 2011;29(suppl):Abstract 4501.
61. Efstathiou E, Titus M, Wen S, et al. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Euro Urol. 2015;67:53-60.
62. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68:4447-4454.
63. Adeniji AO, Chen M, Penning TM. AKR1C3 as a target in castrate resistant prostate cancer. J Steroid Biochem Mol Biol. 2013;137:136-149.
64. Lin HK, Jez JM, Schlegel BP, et al. Expression and characterization of recombinant type 2 3 alpha-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3 alpha/17 beta-HSD activity and cellular distribution. Mol Endocrinol. 1997;11:1971-1984. Erratum in: Mol Endocrinol. 1999;12:1763.
65. Penning TM, Burczynski ME, Jez JM, et al. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J. 2000;351:67-77.
66. Adeniji AO, Twenter BM, Byrns MC, et al. Discovery of substituted 3-(phenylamino) benzoic acids as potent and selective inhibitors of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3). Bioorg Med Chem Lett. 2011;21:1464-1468.
67. Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028-1038.
68. Andersen RJ, Mawji NR, Wang J, et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell. 2010;17:535-546.
69. Agarwal N, Di Lorenzo G, Sonpavde G, et al. New agents for prostate cancer. Ann Oncol. 2014;25:1700-1709.
70. Myung J-K, Banuelos CA, Fernandez JG, et al. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest. 2013;123:2948-2960.